Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q2

3151.TEDINET S100S8PO
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥294.2bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥290.2bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥2.9bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥1.5bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥3.5bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥3.5bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥2.3bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥321.7bnat 2023-09-30Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥316.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥219.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥103.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥30.5bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥26.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥15.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥23.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥23.2bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥16.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥3.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥4.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.0bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥45.782023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.032023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥27.422022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥15.42022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.4%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥108m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥6.6bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥39m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-09-30¥282.5bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-09-30¥277.2bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-09-30¥2.6bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥6m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥114m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.6bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥183m
—segment totalrevenue2023-04-01 → 2023-09-30¥297.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥292.2bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥5.3bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥300.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥294.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥2.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥3.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥146m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥6.4bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥58m
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-09-30¥279.0bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-09-30¥273.8bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-09-30¥1.4bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥9.0bn
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥32m
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥0
jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥182m
—segment totalrevenue2022-04-01 → 2022-09-30¥293.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥288.2bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥5.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥1.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥296.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥290.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 545
ItemContextValueUnit
Other nclPrior1YearInstant10594000000JPY
Other nclCurrentQuarterInstant11789000000JPY
Noncurrent liabilitiesPrior1YearInstant18491000000JPY
Noncurrent liabilitiesCurrentQuarterInstant19157000000JPY
LiabilitiesPrior1YearInstant197150000000JPY
LiabilitiesCurrentQuarterInstant218979000000JPY
Capital stockPrior1YearInstant5000000000JPY
Capital stockCurrentQuarterInstant5000000000JPY
Capital surplusPrior1YearInstant12810000000JPY
Capital surplusCurrentQuarterInstant5272000000JPY
Retained earningsPrior1YearInstant67864000000JPY
Retained earningsCurrentQuarterInstant68809000000JPY
Treasury stockPrior1YearInstant-7575000000JPY
Treasury stockCurrentQuarterInstant-983000000JPY
Shareholders equityPrior1YearInstant78099000000JPY
Shareholders equityCurrentQuarterInstant78099000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant19972000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant22709000000JPY
Remeasurements of defined benefit plansPrior1YearInstant913000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant730000000JPY
Valuation and translation adjustmentsPrior1YearInstant20886000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant23440000000JPY
Non controlling interestsPrior1YearInstant1179000000JPY
Non controlling interestsCurrentQuarterInstant1226000000JPY
Net assetsPrior1YearInstant100165000000JPY
Net assetsCurrentQuarterInstant102766000000JPY
Liabilities and net assetsPrior1YearInstant297316000000JPY
Liabilities and net assetsCurrentQuarterInstant321745000000JPY
Net salesPrior1YTDDuration290166000000JPY
Net salesCurrentYTDDuration294213000000JPY
Cost of salesPrior1YTDDuration267227000000JPY
Cost of salesCurrentYTDDuration270626000000JPY
Gross profitPrior1YTDDuration22939000000JPY
Gross profitCurrentYTDDuration23587000000JPY
Selling general and administrative expensesPrior1YTDDuration21418000000JPY
Selling general and administrative expensesCurrentYTDDuration20719000000JPY
Operating incomePrior1YTDDuration1521000000JPY
Operating incomeCurrentYTDDuration2868000000JPY
Interest income noiPrior1YTDDuration35000000JPY
Interest income noiCurrentYTDDuration33000000JPY
Dividends income noiPrior1YTDDuration384000000JPY
Dividends income noiCurrentYTDDuration326000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration27000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration28000000JPY
Other noiPrior1YTDDuration556000000JPY
Other noiCurrentYTDDuration330000000JPY
Non operating incomePrior1YTDDuration1003000000JPY
Non operating incomeCurrentYTDDuration717000000JPY
Interest expenses noePrior1YTDDuration51000000JPY
Interest expenses noeCurrentYTDDuration50000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass